For better or worse, earnings season is always a nerve-racking time for company executives and their respective shareholders. If a company misses estimates, its stock could drop 5% or more. Despite having a mountain to climb to meet the Wall Street targets, the stocks on our list today could give its shareholders something to cheer about this quarter.
Electronic Arts Inc. (NASDAQ: EA) – $65.93
Toys & Juvenile Products
Electronic Arts Inc. is a game software content and services provider that develops, markets, publishes and distributes game software content for consumers of various video game machines and electronic devices. It also provides game software-related services. The Company’s brands include Battlefield, Mass Effect, Need for Speed, Dragon Age, The Sims, Bejeweled and Plants v. Zombies, as well as brands based on licensed intellectual property such as FIFA, Madden NFL and Star Wars.
- Market Cap: $20,727,983,960
- Next Financial Reporting Date: 28/10/2015
- EPS Estimate (Q3/2015): $0.44
- EPS (Q3/2014): $0.01
Stryker Corp. (NYSE: SYK) – $94.91
Medical Equipment, Supplies & Distribution
Stryker Corporation is a medical technology company that offers a range of products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, which help improve patient and hospital outcomes.
- Market Cap: $36,322,805,322
- Next Financial Reporting Date: 21/10/2015
- EPS Estimate (Q3/2015): $1.23
- EPS (Q3/2014): $0.15
Boston Scientific Corp. (NYSE: BSX) – $16.92
Advanced Medical Equipment & Technology
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Women’s Health, and Neuromodulation.
- Market Cap: $22,739,745,384
- Next Financial Reporting Date: 27/10/2015
- EPS Estimate (Q3/2015): $0.23
- EPS (Q3/2014): $0.03
Interactive Brokers Group Inc. (NASDAQ: IBKR) – $40.66
Financial & Commodity Market Operators
Interactive Brokers Group, Inc. (IBG, Inc.) is a holding company that operates an automated global electronic broker and market maker, specializing in routing orders, and executing and processing trades in securities, futures, foreign exchange instruments, bonds and mutual funds on more than 100 electronic exchanges and trading venues around the world. It operates in two segments: electronic brokerage and market making.
- Market Cap: $15,952,442,837
- Next Financial Reporting Date: 18/10/2015
- EPS Estimate (Q3/2015): $0.30
- EPS (Q3/2014): $0.06
Delta Air Lines Inc. (NYSE: DAL) – $46.96
Airlines
Delta Air Lines, Inc. (Delta) provides scheduled air transportation for passengers and cargo throughout the United States and around the world. The Company’s route network is centered on a system of hub and international gateway airports that it operates in Amsterdam, Atlanta, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle and Tokyo-Narita. Delta’s segments include its Airline segment and Refinery segment.
- Market Cap: $35,689,523,157
- Next Financial Reporting Date: 13/10/2015
- EPS Estimate (Q3/2015): $1.71
- EPS (Q3/2014): $0.43
AbbVie Inc. (NYSE: ABBV) – $56.15
Pharmaceuticals
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company that develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.
- Market Cap: $92,397,525,187
- Next Financial Reporting Date: 25/10/2015
- EPS Estimate (Q3/2015): $1.06
- EPS (Q3/2014): $0.32
